Trial · NCT05654194
Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML
NCT05654194, Phase 3, Completed, The First Affiliated Hospital of Soochow University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML. Trials, record NCT05654194. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05654194
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML
- NCT number
- NCT05654194
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 60 participants, actual
- Lead sponsor
- The First Affiliated Hospital of Soochow University
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Azacitidine Combined With Venetoclax and ATRA group
- First posted
- 2022-12-16
- Last updated
- 2026-06-18
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of the bone marrow complete response | after completion of one induction courses (1st Induction Course is 28 days) and before starting of the 2nd cycle | Rate of the bone marrow complete response after 1 cycle of inductive therapy include Rate of the bone marrow complete response included the rate of the including Complete Remission(CR) and Complete Remission with incomplete hematologic recovery (CRi) after 1 cycle of inductive therapy |
| Secondary | Rate of the bone marrow complete response after 2 cycle of inductive therapy | after completion of two induction courses (1st Induction Course is 28 days) and before starting of the 1st Consolidation cycle | Rate of the bone marrow complete response after 2 cycle of inductive therapy include Rate of the bone marrow complete response included the rate of the including Complete Remission(CR) and Complete Remission with incomplete hematologic recovery (CRi) after 2 cycle of inductive therapy |
| Secondary | Minimal Residual Disease (MRD) response | after completion of two induction courses (one Course is 28 days) and before starting of the 1st Consolidation cycle | MRD response in bone marrow at the end of 2nd cycle |
| Secondary | Overall Survival (OS) | 2 years | time from randomization to death from any cause |
| Secondary | Event Free Survival（EFS） | 2 years | time from randomization to the relapse ,death or drug is unacceptably toxic |
| Secondary | Number of adverse events | 2 years | adverse events are evaluated with CTCAE V5.0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05654194
GET https://conductscience.org/api/trials/v1/NCT05654194/registered